.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,264,423

« Back to Dashboard

Claims for Patent: 5,264,423

Title: Inhibitors for replication of retroviruses and for the expression of oncogene products
Abstract:Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.
Inventor(s): Cohen; Jack S. (Bethesda, MD), Neckers; Len (Bethesda, MD), Stein; Cy (Gaithersburg, MD), Loke; She L. (Wheaton, MD), Shinozuka; Kazuo (Kazo, JP)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Application Number:07/976,733
Patent Claims: 1. A compound capable of inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the compound having the formula: ##STR3## wherein: n is in the range of from 2 to 30, inclusive;

X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and

B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.

2. The compound of claim 1 wherein n is in the range of 14 to 30, inclusive.

3. The compound of claim 2 wherein said foreign nucleic acid is a viral nucleic acid.

4. The compound of claim 3 wherein said viral nucleic acid is a nucleic acid of human immunodeficiency virus.

5. The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a gag gene nucleic acid.

6. The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a tat-III gene nucleic acid.

7. The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a art/trs gene nucleic acid.

8. The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a reverse transcriptase gene nucleic acid.

9. The compound of claim 2 wherein said foreign nucleic acid is an oncogene nucleic acid.

10. The compound of claim 9 wherein said oncogene nucleic acid is a c-myc nucleic acid.

11. The compound of claim 2 wherein greater than 95 percent of X are S.

12. A composition for inhibiting the replication of cytopathic effect of a foreign nucleic acid in a host, the composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of the formula: ##STR4## wherein: n is in the range of from 2 to 30, inclusive;

X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and

B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.

13. The composition of claim 12 wherein n is in the range of 14 to 30, inclusive.

14. The composition of claim 13 wherein said foreign nucleic acid is a viral nucleic acid.

15. The composition of claim 14 wherein said viral nucleic acid is a nucleic acid of human immunodeficiency virus.

16. The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a gag gene nucleic acid.

17. The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a tat-III gene nucleic acid.

18. The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a art/trs gene nucleic acid.

19. The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a reverse transcriptase gene nucleic acid.

20. The composition of claim 13 wherein said foreign nucleic acid is an oncogene nucleic acid.

21. The composition of claim 19 wherein said oncogene nucleic acid is a c-myc nucleic acid.

22. The composition of claim 13 wherein greater than 95 percent of X are S.

23. A method for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host comprising the step of administering to the host an effective amount of a compound of the formula: ##STR5## wherein: n is in the range of from 2 to 30, inclusive;

X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and

B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.

24. The method of claim 23 wherein n is in the range of 14 to 30, inclusive.

25. The method of claim 24 wherein said foreign nucleic acid is a viral nucleic acid.

26. The method of claim 25 wherein said viral nucleic acid is a nucleic acid of human immunodeficiency virus.

27. The method of claim 26 wherein said nucleic acid of human immunodeficiency virus is a reverse transcriptase nucleic acid.

28. The method of claim 27 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.

29. The method of claim 27 wherein at least 95 percent of said X are S.

30. The method of claim 26 wherein said nucleic acid of human immunodeficiency virus is a gag gene nucleic acid.

31. The method of claim 30 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.

32. The method of claim 30 wherein at least 95 percent of said X are S.

33. The method of claim 27 wherein said nucleic acid of human immunodeficiency virus is a tat-III gene nucleic acid.

34. The method of claim 33 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.

35. The method of claim 33 wherein at least 95 percent of said X are S.

36. The method of claim 26 wherein said nucleic acid of human immunodeficiency virus is an art/trs gene nucleic acid.

37. The method of claim 36 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.

38. The method of claim 36 wherein at least 95 percent of said X are S.

39. The method of claim 24 wherein a foreign nucleic acid is an oncogene nucleic acid.

40. The method of claim 39 wherein said oncogene nucleic acid is a c-myc nucleic acid.

41. The method of claim 40 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.

42. The method of claim 41 wherein at least 95 percent of said X are S.

43. A compound capable of inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the compound comprising a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.

44. The compound of claim 43 wherein said mixed linkage oligonucleotide phosphorothioate comprises an alternating sequence of nucleoside moieties and linkage moieties such that the linkage moieties are selected from the group consisting of phosphorothioate, methylphosphonate, phosphorotriester, and phosphodiester.

45. A composition for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the composition comprising a pharmaceutically acceptable carrier and an effective amount of a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.

46. The composition of claim 45 wherein said mixed linkage oligonucleotide phosphorothioate comprise an alternating sequence of nucleoside moieties and linkage moieties such that the linkage moieties are selected from the group consisting of phosphorothioate, methylphosphonate, phosphorotriester, and phosphodiester.

47. A method for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host comprising the step of administering to the host an effective amount of a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.

48. The method of claim 47 wherein said mixed linkage oligonucleotide phosphorothioate comprises an alternating sequence of nucleoside moieties and linkage moieties such that the linkage moieties are selected from the group consisting of phosphorothioate, methylphosphonate, phosphorotriester, and phosphodiester.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc